Action

PI3K δ/ γ

Alt Name

Approval Jurisdiction

2019 FDA

Approved for clinical use

PTCL, brest cancer

Brutto

CAS

1639417-53-0

Commercial Vendor

Rhizen Pharm.

Compound Image

Tenalisib.png

Compound name

Tenalisib

InChI

InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1

InChI Key

HDXDQPRPFRKGKZ-INIZCTEOSA-N

MW

415.40

PubChem CID

86291103

Reference

Reference 2

SMILES

CCC(C1=C(C(=O)C2=CC=CC=C2O1)C3=CC(=CC=C3)F)NC4=NC=NC5=C4NC=N5

Approved Drug List

1